A Review of Botulinum Toxin A for the Treatment of Neurogenic Bladder
2018; Wiley; Volume: 11; Issue: 2 Linguagem: Inglês
10.1016/j.pmrj.2018.07.016
ISSN1934-1563
AutoresLauren Folgosa Cooley, Stephanie Kielb,
Tópico(s)Urological Disorders and Treatments
ResumoPrior to FDA approval of intradetrusor botulinum toxin (BoTA) injections for the treatment of neurogenic bladder, patients' treatment options were limited to use of pharmacotherapies such as antimuscarinics, alpha blockers, and more recently beta agonists (some off‐label) or invasive interventions including bladder augmentation and urinary diversion procedures. Herein, we provide a comprehensive literature review detailing the salient clinical literature that led to FDA approval of intradetrusor BoTA for neurogenic bladder. Patients with neurogenic detrusor overactivity and detrusor sphincter dyssynergia have been shown in randomized studies to benefit significantly from intradetrusor BoTA injection with regard to the following parameters: improved voided volume, improved bladder pressure and urodynamic parameters, reduced incidence of urinary tract infection, and improved quality of life. Intradetrusor BoTA injection has revolutionized the treatment landscape for patients with neurogenic bladder by providing them with a safe, efficacious, and cost‐effective means to reduce bladder dysfunction, preserve renal function, and reduce the need for invasive, surgical intervention. Level of Evidence I
Referência(s)